Connect with us

Health

Limited supply of Mounjaro and Zepbound doses for Lilly, warns FDA, ET HealthWorld

Published

on

Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says, ET HealthWorld

In a recent update from the U.S. Food and Drug Administration (FDA), it has been revealed that most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound will be in limited supply through the second quarter of this year due to increased demand. Both drugs, available in varying doses, are facing constraints in availability, with the 2.5 milligram doses being the only ones listed as fully available.

Previously expected to have limited quantities available through April, the supply of Mounjaro has been consistently limited since February. Additionally, the 1.5 mg and 4.5 mg doses of Trulicity, another diabetes drug by Lilly, will also be in limited supply through April due to the surge in demand.

The rising demand for GLP-1 agonists, a highly effective treatment for diabetes and weight-loss, has caused supply constraints for pharmaceutical companies like Lilly and Novo Nordisk. Lilly has reassured patients of their ongoing investments in manufacturing and supply capacity, with plans to progressively increase production of their medicines throughout 2024 and beyond. Patients are advised to plan ahead for refills by contacting their pharmacy at least one week before the refill is needed.

Mounjaro, approved for patients with type-2 diabetes to control their blood sugar levels since 2022, was also approved in the U.S. for weight loss under the brand name Zepbound late last year. Separately, Lilly announced that tirzepatide, the active ingredient in both Mounjaro and Zepbound, has shown promising results in easing symptoms of a common sleep-related breathing disorder in late-stage studies.

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Trending